EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 787 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR We’re asking scientists to tackle 9 of the toughest challenges in... October 14, 2020 EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin April 30, 2025 Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... March 6, 2020 FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy September 5, 2024 Load more HOT NEWS A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... Rediscovered Drugs Hit Leukemia from Two Different Angles How Becky is helping her children to keep their dad’s memory... FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head...
